Advertisement

Adverse Reactions to Drugs and Drug Allergy: Scope of This Book

  • Brian A. Baldo
  • Nghia H. Pham
Chapter

Abstract

In what is essentially a pharmacologically based classification of adverse drug reactions (ADRs), unpredictable and dose-independent drug reactions, designated type B reactions, include hypersensitivity responses while those reactions designated as type A are predictable, dose-dependent, and make up about 80 % of all ADRs. Previous exposure is not always a prerequisite for allergic sensitization, and there are many instances where reactions occur after initial contact with poorly reactive drugs that do not bind to proteins. Risk factors for drug allergy can be divided into those that are patient-related (age, sex, current diseases, previous exposure, genetic factors) and those that are drug-related (nature and cross-reactivity of drug, degree of exposure, route of administration). Genomic studies are already helping to explain some ADRs, for example, the association in Han Chinese of carbamazepine-induced Stevens–Johnson syndrome with HLA-B*15:02 and the association of abacavir hypersensitivity in abacavir hypersensitivity syndrome with HLA-B*57:01. It seems likely that multiple rather than single genes are involved in ADRs. Drug allergy studies promise to provide significant insights into important areas of biomedical investigation including cell recognition and interaction processes, relationships between receptors and effector pathways and mechanisms of mediator actions.

Keywords

Adverse Drug Reaction Human Leukocyte Antigen Drug Allergy World Allergy Organization Johnson Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Baldo BA, McDonnell NJ, Pham NH. Drug-specific cyclodextrans with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis: implications for drug allergy. Clin Exp Allergy. 2011;41:1663–78.PubMedCrossRefGoogle Scholar
  2. Barone C, Mousa SS, Mousa SA. Pharmacogenomics in cardiovascular disorders: steps in approaching personalized medicine in cardiovascular medicine. Pharmgenomics Pers Med. 2009;2:59–67.PubMedGoogle Scholar
  3. Bharadwaj M, Illing P, Theodossis E, et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol. 2012;52:401–31.PubMedGoogle Scholar
  4. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol. 2012;52:21–35.PubMedGoogle Scholar
  5. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–9.PubMedCrossRefGoogle Scholar
  6. Landsteiner K. The specificity of serological reactions. New York: Dover; 1962.Google Scholar
  7. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med. 1935;61:643–56.PubMedCrossRefGoogle Scholar
  8. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds II. J Exp Med. 1936;64:625–39.PubMedCrossRefGoogle Scholar
  9. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13:1–9.PubMedCrossRefGoogle Scholar
  10. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review. JAMA. 2001;286:2270–9.PubMedCrossRefGoogle Scholar
  11. Rawlins MD, Thomas SHL. Mechanisms of adverse drug reactions. In: Davies DM, Ferner ER, de Glanville H, editors. Davies’ textbook of adverse drug reactions. 5th ed. London: Chapman and Hall Medical; 1998. p. 40–64.Google Scholar
  12. Talbot J, Aronson JK, editors. Stephen’s detection and evaluation of adverse drug reactions. 6th ed. Chichester: Wiley-Blackwell; 2012.Google Scholar
  13. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6:904–16.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Brian A. Baldo
    • 1
  • Nghia H. Pham
    • 1
  1. 1.Formerly-Molecular Immunology Unit Kolling Institute of Medical ResearchRoyal North Shore Hospital of SydneySydneyAustralia

Personalised recommendations